All patients had genomic testing of the primary tumor, and 25 (56%) of the patients had a genomic mutation with 21 (47%) of those patients have a mutation involving mitogen-activated protein kinase (MAPK) pathway. This evidence concerns the gene WNK2 and neoplasm.